SCHEMBL3016859

SCHEMBL3016859

O=S(=O)(c1cccc(C(F)(F)F)c1)C1CCN(c2nc(Cc3ccc(Cl)c(Cl)c3)cs2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 2/20 0.44
AR P10275 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
HRH1 P35367 1/20 0.35
CCR3 P51677 1/20 0.35
HTT P42858 1/20 0.35
POLB P06746 1/20 0.35
KDM1A O60341 1/20 0.35
KMT2A Q03164 1/20 0.34
CCR2 P41597 2/20 0.34
CNR1 P21554 1/20 0.34
CCR1 P32246 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016518 0.93 CTSS (0.43) CTSSARKDM4EMAPTADORA2A
SCHEMBL3015263 0.93 CTSS (0.43) CTSSARKDM4EMAPTADORA2A
SCHEMBL3013043 0.91 CTSS (0.45) CTSSARKDM4EMAPTADORA2A
SCHEMBL3019531 0.91 CTSS (0.46) CTSSARKDM4EMAPTADORA2A
SCHEMBL3015941 0.89 CTSS (0.45) CTSSARKDM4EMAPTADORA2A
SCHEMBL3017861 0.89 GPR6 (0.39) CTSSARMAPTNPC1RAB9A
SCHEMBL3014445 0.89 CTSS (0.47) CTSSARKDM4EMAPTADORA2A
SCHEMBL3001750 0.89 RAB9A (0.39) ARMAPTGAANPC1RAB9A
SCHEMBL3015863 0.88 CTSS (0.44) CTSSARKDM4EMAPTADORA2A
SCHEMBL3006763 0.88 CTSS (0.45) CTSSARKDM4EMAPTADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CTSS 106/4885AR 3801/4885KDM4E 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.